SEC 13F Intelligence

Managers / Q1 2024 · view latest →

Nantahala Capital Management, LLC

CIK 0001472322 · 130 MAIN ST., 2ND FLOOR, NEW CANAAN, CT, 06840 · 203-404-1172

Reported Value
$1.8B
Q1 2024
Positions
124
Filings on Record
32
2019–present window
Filed
May 15, 2024
original filing

Summary

Nantahala Capital Management, LLC reported $1.8B in U.S.-listed holdings across 124 positions for Q1 2024.

Its largest position, SLNOEUR, represents 5.9% of the portfolio.

Compared with Q4 2023, the fund opened 21 new positions and exited 19.

Portfolio Metrics

Turnover
+8.4%
vs prior filed quarter
Top-10 Concentration
+26.9%
share of reported value
Largest Position
+5.9%
Soleno Therapeutics
New / Exited
21 / 19
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $3.3BQ4 ’18Q1 ’19: $3.2BQ2 ’19: $3.2BQ3 ’19: $2.7BQ4 ’19: $3.2BQ4 ’19Q1 ’20: $2.7BQ2 ’20: $3.3BQ3 ’20: $3.3BQ4 ’20: $3.2BQ4 ’20Q1 ’21: $3.4BQ2 ’21: $3.5BQ3 ’21: $3.2BQ4 ’21: $2.8BQ4 ’21Q1 ’22: $2.3BQ2 ’22: $2.0BQ3 ’22: $1.5BQ4 ’22: $1.5BQ4 ’22Q1 ’23: $1.3BQ2 ’23: $1.0BQ3 ’23: $1.2BQ4 ’23: $3.3BQ4 ’23Q1 ’24: $1.8BQ2 ’24: $3.4BQ3 ’24: $2.0BQ4 ’24: $2.3BQ4 ’24Q1 ’25: $2.5BQ2 ’25: $2.6BQ3 ’25: $2.9BQ4 ’25: $3.0BQ4 ’25Q1 ’26: $2.7Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 58.2%ETP: 28.3%Other: 11.6%ADR: 1.1%REIT: 0.5%Other: 0.3%
  • Common Stock · 58.2% · $1.0B
  • ETP · 28.3% · $495M
  • Other · 11.6% · $204M
  • ADR · 1.1% · $19M
  • REIT · 0.5% · $8M
  • Other · 0.3% · $6M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
LLYELI LILLY & CONEW+100.0K100.0K+$78M$78M
GKDGRAND CANYON ED INCNEW+400.0K400.0K+$54M$54M
ISHARES TRNEW+300.0K300.0K+$27M$27M
EGRXEAGLE PHARMACEUTICALS INCNEW+1.26M1.26M+$7M$7M
SLNSILENCE THERAPEUTICS PLCNEW+200.0K200.0K+$4M$4M
MLYSMINERALYS THERAPEUTICS INCNEW+332.5K332.5K+$4M$4M
NEWAMSTERDAM PHARMA COMPANYNEW+175.0K175.0K+$4M$4M
MISTMILESTONE PHARMACEUTICALS INNEW+1.75M1.75M+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2024

41 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SLNOEURSOLENO THERAPEUTICS INChistory →COM5.89%$103M2.41M
2ESTABLISHMENT LABS HLDGS INCCOM5.71%$100M1.96M
3CASHPATHWARD FINANCIAL INChistory →COM2.95%$52M1.02M
4EOLSEVOLUS INChistory →COM2.33%$41M2.91M
5IMAIMAX CORPhistory →COM2.04%$36M2.20M
6HGVHILTON GRAND VACATIONS INChistory →COM1.80%$32M668.9K
7BVSBIOVENTUS INChistory →COM CL A1.72%$30M5.81M
8RDNWRUMBLEON INChistory →COM CL B1.63%$29M4.42M
9PTONPELOTON INTERACTIVE INChistory →CL A COM1.55%$27M6.31M
10RDVTRED VIOLET INChistory →COM1.25%$22M1.12M
11CRMTAMERICAS CAR-MART INChistory →COM1.14%$20M312.1K
12KROSKEROS THERAPEUTICS INChistory →COM1.11%$19M294.0K
13LYRA THERAPEUTICS INCCOM1.00%$18M2.82M
14ABEOABEONA THERAPEUTICS INChistory →COM NEW0.96%$17M2.31M
15UNIQURE NVSHS0.92%$16M3.09M
16TOURMALINE BIO INCCOM0.92%$16M700.9K
17AMRXAMNEAL PHARMACEUTICALS INChistory →COM STK CL A0.91%$16M2.62M
18CDXSCODEXIS INChistory →COM0.89%$16M4.46M
19VMDVIEMED HEALTHCARE INChistory →COM0.84%$15M1.55M
20DXPEDXP ENTERPRISES INChistory →COM NEW0.83%$14M269.8K
21ABVXABIVAX SAhistory →SPONSORED ADS0.83%$14M1.01M
22ZVRAZEVRA THERAPEUTICS INChistory →COM NEW0.81%$14M2.45M
23DYNDYNE THERAPEUTICS INChistory →COM0.71%$12M435.3K
24RSVRRESERVOIR MEDIA INChistory →COM0.70%$12M1.55M
25EHTHEHEALTH INChistory →COM0.66%$12M1.91M
26SNDXSYNDAX PHARMACEUTICALS INChistory →COM0.63%$11M465.3K
27AURAAURA BIOSCIENCES INChistory →COM0.59%$10M1.32M
28NPCENEUROPACE INChistory →COM0.59%$10M778.3K
29GDENGOLDEN ENTMT INCCOM0.57%$10M269.3K
30ASSERTIO HOLDINGS INCCOM NEW0.51%$9M9.27M
31PAYOPAYONEER GLOBAL INCCOM0.51%$9M1.82M
32YB4PSAVARA INCCOM0.49%$9M1.74M
33UNICYCIVE THERAPEUTICS INCCOM0.49%$9M3.34M
34RMRRMR GROUP INCCL A0.47%$8M345.8K
35IMMATICS N.VSHS0.47%$8M788.0K
36ILPTINDUSTRIAL LOGISTICS PPTYS TCOM SHS BEN INT0.46%$8M1.88M
37VTGNVISTAGEN THERAPEUTICS INCCOM0.46%$8M1.52M
38RZLTREZOLUTE INCCOM NEW0.44%$8M3.02M
39NDLSUSDNOODLES & COCOM CL A0.44%$8M4.03M
40CELLECTAR BIOSCIENCES INCCOM NEW0.43%$7M1.87M
41LUXFER HLDGS PLCSHS0.41%$7M685.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$2.7B152May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$3.0B153Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$2.9B153Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$2.6B158Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$2.5B145May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$2.3B137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B140Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024REVEALED$3.4B258Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$1.8B124May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023REVEALED$3.3B255Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$1.2B133Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$1.0B124Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$1.3B124May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.5B118Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.5B120Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$2.0B124Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$2.3B122May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.8B136Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$3.2B130Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$3.5B121Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$3.4B116May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.2B126Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$3.3B130Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$3.3B130Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$2.7B124May 14, 202013F-HRchanges · EDGAR ↗
Q4 2019$3.2B106Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$2.7B108Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$3.2B111Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$3.2B115May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$3.3B124Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.